Executive Summary

The global medical technology (medtech) industry is undergoing a structural transformation driven by shifting pricing policies, evolving healthcare delivery models, trade pressures, and technological convergence. In 2026, five trends are particularly consequential: Mainland China's expanded volume-based procurement (VBP) program, the accelerating migration of procedures to outpatient and ambulatory surgical centers (ASCs), heightened supply chain volatility, the clinical and market ripple effects of GLP-1 receptor agonists, and the rise of platform-based competition underpinned by enabling technologies. These trends are not isolated industry developments—they reflect broader geopolitical, economic, and demographic forces that will shape the global health economy for the next decade.

Introduction

The medtech sector sits at the intersection of healthcare, trade policy, and technology innovation. As governments worldwide seek to contain costs while expanding access, and as digital and physical technologies converge, the industry is becoming a strategic arena for nations and corporations alike. The five trends examined here—derived from a comprehensive report by Clarivate—offer a lens into how the industry is adapting to a more contested, cost-sensitive, and technologically driven world.

Main Analysis

1. Mainland China's VBP Expansion: A Global Pricing Paradigm Shift

China's national volume-based procurement program has evolved from a cost-containment tool into a market-structuring mechanism. The latest round introduces more sophisticated anchor-pricing logic, deeper price reductions, and allocation rules favoring domestic manufacturers. For multinational medtech companies, this is no longer a localized policy issue. The pricing expectations established in China are influencing procurement negotiations in other emerging markets and even developed economies, as global buyers increasingly benchmark against Chinese price levels. Strategic implications: Portfolio strategies must account for a two-tier market—one characterized by high-volume, low-margin domestic production and another by innovation-driven premium segments. Multinationals that fail to adapt risk losing access to one of the world's largest and fastest-growing healthcare markets.

2. The Migration to Outpatient and ASC Settings: Redefining Care Economics

The U.S. Centers for Medicare & Medicaid Services' 2026 final rule expands the ASC covered procedure list, phasing out the inpatient-only list and allowing higher-acuity procedures like cardiac ablation to be performed in lower-cost settings. This trend is global: healthcare systems from Europe to Asia are moving procedures out of hospitals to reduce costs and improve efficiency. For manufacturers, this shift demands new product designs—devices must be compatible with ASC workflows, easier to use, and accompanied by economic value propositions that resonate with outpatient providers. Competition will increasingly focus on total procedure cost rather than device price alone.

3. Supply Chain Resilience and Trade Pressures: A Strategic Imperative

Tariff exposure, geopolitical tensions, and fluctuating material costs are undermining long-standing assumptions about where medtech devices should be manufactured. In response, companies are diversifying suppliers, building multi-region production footprints, and investing in automation and digital supply chain management. Larger firms are leveraging scale to buffer volatility, potentially creating a competitive advantage that reshapes market dynamics. This trend aligns with broader global efforts to secure critical supply chains in medical goods—an area now seen as a matter of national security, not just corporate strategy.

4. GLP-1 Therapies: A Catalyst for Metabolic Care Transformation

The rapid adoption of GLP-1 receptor agonists for weight management and metabolic diseases is having profound effects on medtech demand. Bariatric surgery volumes are under pressure in certain categories, while demand for diabetes care devices, cardiovascular monitoring, and sleep apnea treatments is being reshaped. The effects are uneven, reflecting the complexity of care pathways and the slow evolution of clinical guidelines. What is clear is that GLP-1s are part of a broader shift toward pharma-led management of obesity, with downstream consequences for device makers across multiple specialties.

5. Enabling Technologies and Platform-Based Competition

Robotics, imaging, navigation, and digital workflow software are no longer incremental add-ons—they are becoming the core of integrated care ecosystems. Companies are investing in platform architectures that anchor service lines, deepen customer relationships, and generate data-driven value propositions. Emerging open-platform systems are introducing new competitive dynamics, allowing smaller players to innovate while challenging established incumbents. This shift mirrors broader technology trends in the global economy, where platforms are redefining industries from finance to transportation.

Global Implications

The five trends have far-reaching implications for the global economy and international cooperation. China's VBP program influences global pricing and trade flows, potentially affecting intellectual property protection and innovation incentives. The migration to outpatient care could ease fiscal pressures on health systems, freeing resources for other priorities. Supply chain resilience has become a critical component of global economic security, with governments and corporations pursuing diversification strategies that may reshape regional trade patterns. GLP-1 therapies highlight the interplay between pharmaceuticals and devices, urging cross-sector collaboration in clinical and commercial spheres. Finally, platform-based competition in medtech is contributing to the digital transformation of healthcare, with implications for data privacy, cybersecurity, and equitable access.

Strategic Insights

For business leaders, the key is to recognize that competitiveness no longer depends solely on product performance but on the ability to navigate regulatory, pricing, and trade environments while building ecosystems around enabling technologies. Investors should evaluate medtech firms based on their supply chain resilience, ASC-focused innovation, and platform strategy. Policymakers must balance cost containment with innovation incentives, ensuring that procurement policies do not inadvertently stifle future breakthroughs. International organizations have a role in fostering standards for data exchange and cybersecurity, as well as facilitating trade agreements that address the unique characteristics of medical products.

Future Outlook

Over the next three to ten years, these trends will intensify. China's VBP is likely to drive further consolidation in the domestic industry and spur outward investment by Chinese firms in emerging markets. The shift to ASCs will accelerate as new payment models and technological advances enable more procedures to be performed safely and cost-effectively outside hospitals. Supply chains will become more regionalized and digitized, with an emphasis on redundancy and verification. GLP-1 therapies will continue to reshape metabolic care, potentially expanding into combination therapies and new indications. Enabling technologies will mature, leading to greater integration of AI and machine learning in diagnostics and surgical planning. These developments will create both opportunities and challenges, requiring continuous adaptation from all stakeholders.

Conclusion

The medtech industry in 2026 is a microcosm of the broader global transformations under way—governments seeking to balance cost and access, businesses navigating geopolitical tensions, and technologies breaking down traditional boundaries. The five trends examined here are not transient fads but structural shifts that will define the industry for years to come. For those with strategic foresight, the response lies not in reacting to individual challenges but in building resilient, adaptive, and globally integrated models that can thrive in an era of constant change.

Key Takeaways

• Mainland China's VBP expansion is redefining global pricing and market structure, requiring multinationals to adopt dual-market strategies.
• The shift to outpatient and ASC settings is altering device design, commercial models, and competitive dynamics.
• Supply chain resilience has become a strategic weapon, with scale and diversification conferring significant advantages.
• GLP-1 therapies are reshaping metabolic care pathways, with uneven but consequential effects across device categories.
• Enabling technologies are driving a move toward platform-based competition that will dominate medtech strategy in the coming decade.

Sources

• Clarivate: Medtech Trends to Watch in 2026